South Korea’s Samsung Bioepis Co Ltd reported it commenced U.S sales of its copy of Johnson & Johnson’s rheumatoid arthritis drug Remicade on Monday – a shift set to even more undermine sales of the U.S. firm’s top rated-marketing drug.
SEOUL: South Korea’s Samsung Bioepis Co Ltd reported it commenced U.S sales of its copy of Johnson & Johnson’s rheumatoid arthritis drug Remicade on Monday: a shift set to even more undermine sales of the U.S. firm’s top rated-marketing drug.
It is the second less costly biosimilar variation of Remicade to be bought immediately after Pfizer Inc’s Inflectra. Remicade experienced U.S. sales of US$four.8 billion previous year, but January-June sales fell 8.two percent from a year before to US$two.two billion on its new competition.
A Johnson & Johnson unit, Janssen Biotech Inc, has sought a preliminary or lasting U.S. courtroom injunction to block Bioepis’s variation, arguing that the South Korean agency violated 3 of its patents. A listening to for the lawsuit has but to be scheduled.
“We are assured we do not infringe on Janssen’s patents,” Samsung Bioepis spokesman Mingi Hyun instructed Reuters in a assertion.
Samsung Bioepis, an unlisted unit of contract drug company Samsung BioLogics Co Ltd, acquired U.S regulatory acceptance to start its biosimilar, Renflexis, in April. Biosimilars are lower-charge variations of intricate biotech medicine, and Bioepis has targeted on developing copies of some of the world’s top rated marketing medicine.
Drugmakers in the previous have pushed ahead with sales of items that have been matter to patent litigation, but they can facial area major penalties if they lose in courtroom.
A U.S. judge in 2013 awarded AstraZeneca Plc US$76 million in damages from generic drug maker Apotex for patent infringement for AstraZeneca’s heartburn drug Prilosec, or the equal of 50 percent of revenue created all through the 3-and-a-50 %-year time period Apotex bought a generic variation of Prilosec.
(Reporting by Se Youthful Lee Enhancing by Edwina Gibbs)